WeSearch

STAT+: Will Makary’s FDA voucher program survive?

Meghana Keshavan· ·1 min read · 0 reactions · 0 comments · 41 views
STAT+: Will Makary’s FDA voucher program survive?

RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news

About this source

STAT News files mainly under health. We currently carry 208 of its stories.

All STAT News coverage →
Original article
STAT · Meghana Keshavan
Read full at STAT →
Anonymous · no account needed
Share 𝕏 Facebook Reddit LinkedIn Threads WhatsApp Bluesky Mastodon Email

Discussion

0 comments

More from STAT

STAT+: Up and down the ladder: The latest comings and goings
STAT+: Up and down the ladder: The latest comings and goings
STAT5 views
 There are already more U.S. measles cases this year than in all of 2025
There are already more U.S. measles cases this year than in all of 2025
STAT4 views
 FDA advisory panel narrowly rejects compounding of one peptide, backs two others
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
STAT5 views
 Opinion: I led the FDA’s food safety and nutrition center. Here’s what people are missing about the cyclospora outbreak
Opinion: I led the FDA’s food safety and nutrition center. Here’s what people are missing about the cyclospora outbreak
STAT4 views
 White House offers its science blueprint: More AI, less life sciences
White House offers its science blueprint: More AI, less life sciences
STAT4 views
 Opinion: The U.S. pharmaceutical supply chain problem is not about China
Opinion: The U.S. pharmaceutical supply chain problem is not about China
STAT10 views